<DOC>
	<DOC>NCT00389987</DOC>
	<brief_summary>This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.</brief_summary>
	<brief_title>Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)</brief_title>
	<detailed_description>Original label approved November 2001</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>Male or female patients (greater or equal to 18 years of age) Intraoperative/Postoperative Enrollment: Upon visual confirmation of an intraabdominal infection. Preoperative Enrollment: Patients may be enrolled preoperatively if they meet certain criteria Failure to meet all inclusion criteria. Patients who are considered unlikely to survive the 68 week study period. Pregnant or nursing women, or fertile women not practicing adequate methods of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>